Guidance, NICE advice and quality standards in development | Guidance

Showing 21 to 30 of 405

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Artificial intelligence (AI) technologies for assessing and triaging skin lesions within the urgent suspected skin cancer pathway	Health technology evaluation	19 December 2024
Artificial intelligence software to help detect and characterise colorectal polyps	Diagnostics guidance	TBC
Artificial intelligence technologies to help detect fractures on X-rays in urgent care	Health technology evaluation	14 January 2025
Asthma: diagnosis, monitoring and chronic asthma management	NICE guideline	27 November 2024
Asunercept for treating glioblastoma [1301]	Technology appraisal guidance	TBC
Atezolizumab (Tecentriq) + bevacizumab (Avastin) + chemotherapy for ovarian cancer TS ID 10701	Technology appraisal guidance	TBC
Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]	Technology appraisal guidance	TBC
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer (MA review of TA823) [ID6324]	Technology appraisal guidance	23 July 2025